Provided by: Chunghwa Chemical Synthesis & Biotech Co.,Ltd
SEQ_NO
2
Date of announcement
2022/08/09
Time of announcement
16:55:54
Subject
The board of directors approved the appointment of
the general manager.
Date of events
2022/08/09
To which item it meets
paragraph 6
Statement
1.Date of the board of directors resolution or date of occurrence of the
change:2022/08/09
2.Position (Please enter chairperson or president/general manager):
general manager
3.Name of the previous position holder:Jong-shinn Huang
4.Resume of the previous position holder:General Manager,
Chunghwa Chemical Synthesis & Biotech Co., Ltd.
5.Name of the new position holder:Ching-Peng Wei
6.Resume of the new position holder: Vice President of Research &
Development Division, Chunghwa Chemical Synthesis & Biotech Co., Ltd.
7.Circumstances of change (Please enter "resignation", "dismissal",
"term expired" , "job relocation", "severance", "retirement",
"death" or "new appointment"):new appointment
8.Reason for the change: The former general manager resigned due to
personal career planning, and the board of directors approved the
appointment of the new general manager.
9.Effective date of the new appointment:2022/09/01
10.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
Chunghwa Chemical Synthesis & Biotech Co. Ltd. published this content on 09 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 August 2022 11:25:05 UTC.
CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the manufacture and distribution of biotechnology products and chemical synthetic products. The Company's biotechnology products include pravastatin, rapamycin, tacrolimus, everolimus, mycophenolate mofetil, mycophenolic acid sodium and others. Its non-biotechnology products include methocarbamol, guaifenesin, trandolapril, fluconazole, olopatadine, dexbromopheniramine maleate and glipizide, among others. Its products are applied in the manufacture of drugs for treatment of cough, diabetes, cardiovascular diseases, high blood pressure and immune system diseases. The Company distributes its products within domestic market and to overseas markets, including the rest of Asia, the Americas and Europe.